These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20739727)

  • 1. Novel therapies for hypereosinophilic syndromes.
    Antoniu SA
    Neth J Med; 2010 Aug; 68(1):304-10. PubMed ID: 20739727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical management of the hypereosinophilic syndromes.
    Cogan E; Roufosse F
    Expert Rev Hematol; 2012 Jun; 5(3):275-89; quiz 290. PubMed ID: 22780208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.
    Schwartz LB; Sheikh J; Singh A
    Curr Med Res Opin; 2010 Aug; 26(8):1933-46. PubMed ID: 20565230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-IL-5 and hypereosinophilic syndromes.
    Sutton SA; Assa'ad AH; Rothenberg ME
    Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of FIP1L1/PDGFRA-negative hypereosinophilic syndrome with alemtuzumab, an anti-CD52 antibody.
    Wagner LA; Speckart S; Cutter B; Gleich GJ
    J Allergy Clin Immunol; 2009 Jun; 123(6):1407-8. PubMed ID: 19342084
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of hypereosinophilic syndromes--the first 100 years.
    Butterfield JH; Weiler CR
    Semin Hematol; 2012 Apr; 49(2):182-91. PubMed ID: 22449628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
    Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
    J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel approaches to therapy of hypereosinophilic syndromes.
    Simon HU; Cools J
    Immunol Allergy Clin North Am; 2007 Aug; 27(3):519-27. PubMed ID: 17868862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
    Williams AK; Dou C; Chen LYC
    Br J Haematol; 2021 Dec; 195(5):669-680. PubMed ID: 34105142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypereosinophilic syndrome: an update.
    Wilkins HJ; Crane MM; Copeland K; Williams WV
    Am J Hematol; 2005 Oct; 80(2):148-57. PubMed ID: 16184589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
    Hellmich B; Holl-Ulrich K; Gross WL
    Dtsch Med Wochenschr; 2007 Sep; 132(37):1892-6. PubMed ID: 17823882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypereosinophilic syndrome: diagnosis and treatment.
    Peros-Golubicić T; Smojver-Jezek S
    Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia.
    Kalac M; Quintás-Cardama A; Vrhovac R; Kantarjian H; Verstovsek S
    Cancer; 2007 Sep; 110(5):955-64. PubMed ID: 17654661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
    Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The hypereosinophilic syndromes: still more heterogeneity.
    Gleich GJ; Leiferman KM
    Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K; Wilson WH
    Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.